Latest Research in Neurology (2025-2026)

1. Stroke - New Guidelines & Drug Developments

• Asundexian, an oral anticoagulant (Factor XIa inhibitor), showed promise in a Phase 3 trial published in the NEJM (April 2026) for reducing secondary ischemic stroke risk after a first ischemic stroke or high-risk TIA - potentially an alternative to current antiplatelet therapy.
• Stroke biomarkers are rapidly advancing: a 2026 Lancet Neurology review by Tiedt et al. highlights blood-based markers (NfL, GFAP, glial proteins) enabling earlier diagnosis, triage, and outcome prediction.
• The ESO Annual Stroke Evidence Update 2025 (de Sousa et al., Eur Stroke J, Feb 2026) consolidated advances in thrombectomy timing, neuroprotection, and post-stroke rehabilitation.
• Mediterranean diet was associated with reduced stroke risk in women, including both ischemic and hemorrhagic subtypes, per a 2025-2026 Neurology publication.

2. Alzheimer's Disease - Immunotherapy & Glymphatic Research

• Anti-amyloid antibodies (lecanemab, donanemab) are now entering real-world use after landmark trial approvals. Active research is exploring oral maintenance therapy after plaque clearance - valiltramiprosate (Alzheon) is in Phase 3/2 trials (APOLLOE4 study) specifically in APOE4/4 patients, with Phase 3 data to be presented at AAIC 2026 in London.
• Immune dysfunction in Alzheimer's is a major 2026 research theme. A Nature Reviews Neuroscience review by Butovsky et al. (Mar 2026) identifies microglia and peripheral immune cells as central drivers of neurodegeneration - with potential for immunomodulatory therapies.
• Glymphatic system dysfunction in AD was critically appraised in a Science review by Keil et al. (Jul 2025), raising questions about the role of cerebrospinal fluid clearance during sleep in amyloid/tau accumulation.
• A comprehensive Lancet two-part series (Fox et al. + Frisoni et al., Sep 2025) reviewed current treatment challenges and future directions, including precision staging with plasma biomarkers.

3. Parkinson's Disease - Gut-Brain Axis & Novel Targets

• The gut-brain-microbiota axis has emerged as a leading research focus. A 2025 Neuroscience review (Yadav & Raj) shows dysbiosis precedes motor symptoms in many PD patients, opening the door to microbiome-targeted interventions.
• FGF21 and ACE2 signaling pathways are being explored as synergistic neuroprotective targets (Liu et al., Ageing Res Rev, 2025).
• Metformin's role on astrocytes in PD is under investigation, with implications for repurposing this widely available drug (Al-Kuraishy et al., Mol Neurobiol, 2025).
• Branched-chain amino acids (BCAAs) are being studied for neuroprotection in PD, with mechanistic and therapeutic implications (Huang et al., Int J Mol Sci, 2025).

4. ALS - Gene Therapy & iPSC Advances

• Tofersen (antisense oligonucleotide targeting SOD1) has been reviewed as a novel treatment option specifically for SOD1-ALS, representing a precision medicine approach for a genetic subtype (Karros et al., Ann Pharmacother, 2026).
• A comprehensive 2026 review in Regenerative Therapy (Morimoto et al.) covers iPSC-based drug discovery, cell therapy, and gene therapy advances through 2026 - noting that iPSC-derived motor neurons are now used to screen candidate drugs and model patient-specific ALS.
• The gut-brain-immune axis in ALS is under active investigation (Mudda et al., Front Immunol, 2025), paralleling Parkinson's research.

5. Multiple Sclerosis - Neuroinflammation Biomarkers

• A 2026 systematic review in Cells (Gavrilă et al.) catalogued neuroinflammation biomarkers in MS, including neurofilament light chain (NfL), chitinase-3-like protein 1 (CHI3L1), and GFAP - moving toward blood-based monitoring to replace invasive CSF testing.
• MicroRNA-155 is emerging as a regulator of neurodegeneration and immune activation across MS and other diseases (Liu & Siadat, Clin Chim Acta, 2026).
• Drug safety in MS immunosuppression (malignancy risk with long-term use of natalizumab, fingolimod, cladribine) is increasingly studied as patients survive longer on disease-modifying therapy (Dalla Costa & Comi, Expert Opin Drug Saf, 2026).

6. Neuroimmunology - MOGAD

• MOGAD (MOG antibody-associated disease) is now recognized as a distinct entity from MS and NMOSD. Practical recommendations for diagnosis and management were published in J Neuroimmunol (Sechi et al., Jan 2026), covering steroid-sparing therapies and relapse prevention.

7. Brain-Computer Interfaces (BCIs) & Neurotech

• The global BCI market reached $3.21 billion in 2025 and is projected to hit $15 billion by 2035 (16.7% annual growth). BCIs are transitioning from research labs into approved clinical practice for conditions like treatment-resistant depression, spinal cord injury, and ALS.
• Neuralink led $650M in funding in 2025; speech restoration and motor control via BCIs have demonstrated early clinical proof-of-concept.
• Closed-loop AI-powered neuromodulation - systems that sense neural states and adapt stimulation in real time - is the next frontier for Parkinson's DBS, epilepsy management, and neurorehabilitation.
• The European Academy of Neurology hosted a major 2026 debate (April 29): "AI in Neurology: Augmentation or Automation?" - addressing whether AI diagnostic tools for MRI, EEG, and NCS can match or exceed neurologist performance.

8. Vascular Cognitive Impairment & Dementia

• A 2026 JACC review (Sachdev et al.) provides an updated framework for vascular cognitive impairment and dementia (VCID), integrating white matter lesion burden, microbleeds, and neuroimaging biomarkers with clinical features - emphasizing cardiometabolic risk factor control as the primary prevention strategy.

9. Neurodiagnostics - AI & Advanced Tools

• A 2026 review in Int Rev Cell Mol Biol (Dave et al.) reviewed advances in neurodiagnostic tools, including AI-enhanced EEG analysis, ultra-high-field MRI (7T), optical coherence tomography of the retina as a CNS window, and digital biomarkers from wearables.

Key Themes Across Neurology in 2026